How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

601. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. Full Text available with Trip Pro

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats.DIO rats were intraperitoneally injected with a single dose of amylin (10 microg kg(-1)) and/or phentermine (1 mg kg(-1)) or chronically infused with amylin (100 microg kg(-1) d(-1)) or vehicle (...) with or without phentermine (0.5-10 mg kg(-1) d(-1)) or sibutramine (3 mg kg(-1) d(-1)) using two surgically implanted subcutaneous osmotic mini-pumps.Twenty-four hour food intake, locomotor activity and components of meal microstructure (meal size, latency, duration and intermeal interval) were measured following acute administration (amylin, phentermine or amylin+phentermine). Body weight and composition (for amylin and/or sibutramine or phentermine) and metabolism-related gene mRNA expression in the liver

2008 International Journal of Obesity

602. Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs. Full Text available with Trip Pro

Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs. Sibutramine, a serotonin-norepinephrine uptake inhibitor, has been used for treating obesity. However, its possible mechanisms involving gastric motility have not been reported. The aim of this study was to evaluate the effects of sibutramine on gastric accommodation and antral motility.The study was performed in seven dogs with a stomach cannula and composed of two separate experiments: antral contractions (...) and gastric tone. Each experiment included two sessions on 2 separate days in a randomized order: a control session and a treatment session with sibutramine (5 mg/kg per os) administrated 2 hours before the study.Sibutramine significantly increased fasting gastric tone; the gastric volume in the fasting state at baseline was 103.8 +/- 12.3 mL and significantly decreased to 35.3 +/- 16.0 mL with sibutramine (p = 0.0075). Sibutramine also impaired gastric accommodation. The average postprandial gastric

2006 Obesity

603. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. (Abstract)

Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. To study the associations between weight loss with sibutramine and orlistat with psychological aspects that may interact with patients' response to these drugs.A total of 478 obese patients with a mean body mass index of 42 +/- 12 kg/m(2) gave self-reported, retrospective data on different types of previous weight loss treatments (sibutramine and orlistat, and Weight Watchers used as a control (...) condition) including the amount of weight lost with these treatments, eating behaviour (Dutch Eating Behaviour Questionnaire) and personality (NEO Personality Inventory - Revised).Greater weight loss with sibutramine was associated with lower levels of restrained eating and higher levels of 'neuroticism', in particular 'anxiety' and 'depression'. Greater weight loss with orlistat was associated with aspects of the personality dimension 'conscientiousness' (e.g. 'order' and 'deliberation').Sibutramine

2008 obesity & metabolism

604. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Full Text available with Trip Pro

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Observational cohort studies were conducted using prescription-event monitoring (PEM) to examine the safety profiles of the anti-obesity agents orlistat and sibutramine. Adverse events reported as case reports were also evaluated to determine whether these events were also identified by PEM.Patients were identified from dispensed prescriptions written by general practitioners (GPs (...) ) in England for orlistat or sibutramine. Patient demographic and clinical event information, including reasons for stopping and adverse drug reactions, were requested on questionnaires posted to GPs at least 6 months after the first prescription for individual patients. Event incidence densities (IDs) (number of first reports of event/1000 patient-months treatment) were calculated for month 1 (ID(1)) and months 2-3 (ID(2-3)). Published case reports were identified by searching Medline and Embase.The

2007 Obesity

605. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Full Text available with Trip Pro

Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. To further address the function of the Y5 receptor in energy homeostasis, we investigated the effects of a novel spironolactone Y5 antagonist in diet-induced obese (DIO) mice.Male C57BL/6 or Npy5r(-/-) mice were adapted to high-fat (HF) diet for 6-10 months and were submitted to three experimental treatments. First, the Y5 antagonist at a dose of 10 or 30 mg/kg was administered for 1 month to DIO (...) C57BL/6 or Npy5r(-/-) mice. Second, the Y5 antagonist at 30 mg/kg was administered for 1.5 months to DIO C57BL/6 mice, and insulin sensitivity was evaluated using an insulin tolerance test. After a recovery period, nuclear magnetic resonance measurement was performed to evaluate body composition. Third, DIO mice were treated with the Y5 antagonist alone, or in combination with 10% food restriction, or with another anorectic agent, sibutramine at 10 mg/kg, for 1.5 months. Plasma glucose, insulin

2008 Obesity

606. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand. Full Text available with Trip Pro

Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand. To determine whether postmarketing data provide evidence of an association of sibutramine with bruising.During a postmarketing surveillance study of sibutramine in New Zealand by the Intensive Medicines Monitoring Programme (IMMP), a series of reports of bruising was identified. Further case reports were also obtained from the World Health Organisation (WHO) adverse drug reactions database.All platelet (...) , bleeding and clotting events associated with sibutramine were identified and causality assessments were performed.From the IMMP and WHO databases a total of 16 cases of bruising that improved on withdrawal of sibutramine were identified. Of these, two had a recurrence of bruising on reintroduction of sibutramine.Evidence from postmarketing surveillance suggests that there is a causal association between sibutramine and bruising/ecchymosis. This represents a newly recognized adverse reaction

2006 International Journal of Obesity

607. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. Full Text available with Trip Pro

The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. Obstructive sleep apnoea (OSA) occurs frequently in obese patients and may be reversible with weight loss. Obstructive sleep apnoea and obesity are both independent risk factors for hypertension and increased sympathetic activity. Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension. No studies have investigated the effect (...) of sibutramine on OSA, blood pressure and heart rate. We aimed to assess the changes in OSA and cardiovascular parameters in obese men with OSA enrolled in a sibutramine-assisted weight loss programme (SIB-WL).Open uncontrolled cohort study of obese male subjects with OSA in an SIB-WL.Eighty-seven obese (body mass index =34.2+/-2.8 kg/m(2)) middle-aged (46.3+/-9.3 years) male subjects with symptomatic OSA (Epworth score 13.4+/-3.6; respiratory disturbance index (RDI) 46.0+/-23.1 events/h) completed

2007 International Journal of Obesity

608. Assessment of the Application of the Intragastric Balloon Together with Sibutramine: A Prospective Clinical Study. (Abstract)

Assessment of the Application of the Intragastric Balloon Together with Sibutramine: A Prospective Clinical Study. The aim of this study is the prospective evaluation of the results of Bioenterics intragastric balloon (BIB) with sibutramine and BIB placement alone in the treatment of obesity.The patients evaluated between March 2006 and January 2007 and enrolled in this study were assessed in two groups as group A (BIB + sibutramine) and group B (BIB). After the follow-up of the patients for 6 (...) in group A had a mean BMI 34.53 +/- 6.63 kg/m(2), EWL% 38.77 +/- 11.88%, EBMIL% 49.93 +/- 21.52% after 6 months; the patients in group B had a mean BMI 35.29 +/- 6.36 kg/m(2), EWL% 29.06 +/- 17.82%, EBMIL% 36.51 +/- 23.69% after 6 months. There was no statistically significant difference between group A and group B according to the BMI, EWL%, and EBMIL% values (p > 0.05).In the management of obesity, using BIB together with sibutramine before the treatment in the patient group who are planned to have

2008 Obesity Surgery

609. Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. Full Text available with Trip Pro

Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. The serotonin and norepinephrine transporter inhibitor sibutramine is a widely used antiobesity drug. In acute studies, the peripheral sympathomimetic effect of sibutramine was counteracted by a central sympatholytic action.The objective was to test the hypothesis that blood pressure responses to long-term sibutramine therapy may be related to sympathetic nerve traffic before treatment (...) in a prospective open-label study in an academic clinical research center.This study comprised 20 obese subjects (body mass index, 30-40 kg/m2; age, 30-57 yr) receiving 5 d of placebo treatment followed by open-label 15 mg/d sibutramine and hypocaloric diet over 12 wk.Body weight, blood pressure, heart rate, muscle sympathetic nerve activity (MSNA) (microneurography), plasma catecholamines, and adipose tissue gene expression were measured.Open-label sibutramine treatment decreased body weight 4.1 kg (P<0.01

2007 Journal of Clinical Endocrinology and Metabolism

610. Severe Symptomatic Hyponatremia During Sibutramine Therapy: A Case Report. (Abstract)

Severe Symptomatic Hyponatremia During Sibutramine Therapy: A Case Report. Sibutramine, a serotonin reuptake inhibitor, currently is used in treatment of obesity. The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects. We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman. We hypothesize that sibutramine, through its effect on neurotransmitters, may induce antidiuretic hormone (...) secretion and lead to a syndrome of inappropriate antidiuretic hormone secretion. We advise careful monitoring of water-electrolytic balance during sibutramine therapy.

2008 American Journal of Kidney Diseases

611. Long-term weight loss with sibutramine: a randomized controlled trial. (Abstract)

Long-term weight loss with sibutramine: a randomized controlled trial. Treatment of obesity requires long-term therapy, which can be hampered by difficulties in achieving patient compliance. The effectiveness of sibutramine hydrochloride in treating obesity has been shown in randomized controlled trials.To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons.Randomized, double-blind, parallel-group placebo (...) -controlled trial from April 1997 to September 1998.One hundred eight private practices and 3 outpatient departments of university hospitals in Germany.A total of 1102 obese adults (body mass index, 30-40 kg/m(2)) entered the 4-week open-label run-in period with 15 mg/d of sibutramine, 1001 of whom had weight loss of at least 2% or 2 kg were randomized into the 44-week randomized treatment period.Patients were randomly assigned to receive 15 mg/d of sibutramine continuously throughout weeks 1-48 (n = 405

2001 JAMA Controlled trial quality: predicted high

612. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. Full Text available with Trip Pro

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. Adolescent obesity is becoming a national public health problem. Weight-loss medications including sibutramine facilitate weight control in adults and could be used with obese adolescents in combination with behavior therapy (BT).To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program.Randomized (...) , double-blind, placebo-controlled trial consisting of 82 adolescents aged 13 to 17 years with a body mass index (BMI) of 32 to 44 conducted from March 1999 to August 2002 at a university-based clinic for 6 months, followed by open-label treatment during months 7 to 12.For the first 6 months, participants received either BT and sibutramine or BT and placebo. From months 7 to 12, all participants received sibutramine in open-label treatment.Percentage change in BMI; systolic and diastolic blood pressure

2003 JAMA Controlled trial quality: predicted high

613. Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates

Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Sibutramine (...) Institute (NHLBI) Information provided by (Responsible Party): University of Tennessee Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking. Condition or disease Intervention/treatment Phase Cardiovascular Diseases Heart Diseases Obesity Drug: Sibutramine Behavioral: Behavioral Smoking Cessation Program Not Applicable Detailed

2002 Clinical Trials

614. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias Full Text available with Trip Pro

Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias 12041851 2002 06 21 2018 11 13 0820-3946 166 10 2002 May 14 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. 1307-8 Wooltorton Eric E eng Journal Article Canada CMAJ 9711805 0820-3946 0 Appetite Depressants 0 Cyclobutanes WV5EC51866 sibutramine AIM IM Appetite Depressants adverse effects therapeutic use

2002 CMAJ: Canadian Medical Association Journal

615. Sibutramine--a review of clinical efficacy. (Abstract)

Sibutramine--a review of clinical efficacy. Controlled studies have shown that sibutramine produces dose-related weight loss when given in the range 5-30 mg per day, with optimal doses of 10 and 15 mg per day. Weight loss with sibutramine is 3-5 kg better than placebo at 24 weeks, and weight loss is maintained to 52 weeks at doses of 10 and 15 mg. By six months, 69% of patients treated with sibutramine 15 mg achieve a 5% or greater reduction in their baseline weight. The weight loss achieved (...) with sibutramine was similar to that achieved with dexfenfluramine over 12 weeks (4.5 kg compared with 3.2 kg). Sibutramine-induced weight loss has been found to be accompanied by a significant reduction in waist/hip ratio, and decreases in plasma triglycerides, total cholesterol and low density lipoprotein (LDL) cholesterol. There were also increases in high density lipoprotein (HDL) cholesterol. In patients with type II diabetes, sibutramine-induced weight loss was accompanied by a shift towards improved

1997 International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity

616. Sibutramine: a novel new agent for obesity treatment. (Abstract)

Sibutramine: a novel new agent for obesity treatment. Sibutramine is a novel new pharmacologic agent which is a specific reuptake inhibitor for norepinephrine and serotonin. Preclinical data show that sibutramine and its two metabolites reduce food intake of animals eating either high or low carbohydrate diets and of obese Zucker rats. An 8-week clinical trial showed a dose-dependent decrease on body weight. Sibutramine, 5 and 20 mg/day, produced a dose-related weight loss in obese subjects (...) compared to placebo in an 8-week trial. In doses varying from 1 to 30 mg, sibutramine also produced a dose-dependent decrease in weight in the healthy obese population when used in 6-,8-,12-24- and 52-week trials. Although the majority of the weight loss occurred during the first 12 weeks of treatment, weight loss had not plateaued in by 24 weeks in the higher doses. Side effects were mild. This drug shows promise as an antiobesity drug.

1995 Obesity research

617. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. (Abstract)

An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Sibutramine is a combined serotonin(5-HT) and noradrenaline (NA)re-uptake inhibitor. Sibutramine works predominantly through its two pharmacologically active metabolites (i.e. primary and secondary amines) which induce marked weight loss by affecting both food intake and energy expenditure. It is able to enhance the physiological process of satiety, and to stimulate thermogenesis (...) , increasing the efferent sympathetic activity to thermogenically active brown fat. There is a dose-related reduction in body weight in clinical trials with sibutramine, with weight loss up to 11% below baseline, which can last up to 18 months with continued treatment. When weight loss is induced with a very low calorie diet (VLCDL), patients randomized to the sibutramine treatment continued to lose weight over a 1 year period, reaching 15% below baseline, whereas the placebo-treated patients regained some

2000 Obesity reviews : an official journal of the International Association for the Study of Obesity

618. [Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine]. (Abstract)

[Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine]. The results of the "Sibutramine Trial of Obesity Reduction and Maintenance" (STORM) published in the last issue of December 2000 of the Lancet are summarized. This clinical trial (open label for the first 6 months and double blind versus placebo for a further 18 months) demonstrates the positive effect of sibutramine, a new anorectic drug, on long-term weight maintenance after weight (...) loss in obese subjects. The benefit of sibutramine on the cardiovascular risk profile of the obese patient is more particularly discussed.

2001 Revue médicale de Liège

619. Sibutramine in weight control: a dose-ranging, efficacy study. (Abstract)

Sibutramine in weight control: a dose-ranging, efficacy study. We tested the safety and efficacy of sibutramine, 5 and 20 mg, and placebo on weight loss. Medication was added to caloric restriction, behavior modification, and exercise in a parallel-group, double-blind clinical trial. Participants were 130% to 180% of ideal body weight and in good health. The study lasted 12 weeks over Thanksgiving, Christmas, and New Year's Day. Weight loss during 8 weeks of study medication was: placebo, 1.4 (...) +/- 2.1 kg (n = 19); 5 mg sibutramine, 2.9 +/- 2.3 kg (n = 18); and 20 mg sibutramine, 5.0 +/- 2.7 kg (n = 18) (p less than 0.05 sibutramine, 5 and 20 mg, versus placebo; p less than 0.05 sibutramine, 20 mg versus 5 mg). There is a significant dose-effect relationship. Five participants left the study before completion, all because of adverse events; placebo (one patient), 5 mg sibutramine (one patient), and 20 mg sibutramine (three patients). Sleep difficulties were noted by eight participants (20 mg

1991 Clinical pharmacology and therapeutics Controlled trial quality: uncertain

620. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? (Abstract)

Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Visceral adiposity has a strong and independent association with obesity and its related co-morbidities, particularly metabolic complications such as cardiovascular disease and type II diabetes. Waist circumference and waist-to-hip ratio (WHR) are both secondary indicators of visceral obesity. This paper examines the effect of sibutramine, a new serotonin and noradrenaline re-uptake (...) inhibitor, on weight reduction and changes in fat distribution. A meta-analysis of four long-term, placebo-controlled, double-blind studies showed significantly greater mean decreases in waist circumference in sibutramine-treated subjects compared with placebo (P < 0.001). Similar results were seen for WHR, with 15 mg sibutramine daily producing a significant reduction of 0.02 compared with placebo (P < 0.02). Changes in fat distribution have been examined using computerised tomography (CT) scans

1998 International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>